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associatedMITFmutations (p.R217I and p.T192fsX18). The R217I MITF retained partial activity, nor-
mal DNA-binding ability and nuclear distribution, whereas the T192fsX18 MITF failed to activate
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Microphthalmia-associated transcription factor (MITF), a basic
helix–loop–helix leucine zipper (bHLHZip) transcription factor,
plays a key role in survival and differentiation of melanocytes
[1–4]. In melanocytes, MITF regulates the expression of major
melanogenic genes such as tyrosinase (TYR), tyrosinase-related
protein-1 (TYRP1), and tyrosinase-related protein-2 (TYRP2)
[5,6]. MITF directly upregulates the expression of TYR, TYRP1,chemical Societies. Published by E
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ong@xysm.net (Y. Feng).and TYRP2 by binding to the E-box motif (CANNTG) within the
promoter [4,6–9]. These genes encode enzymes required for
normal melanin synthesis in melanocytes [7,9,10]. The three en-
zymes, especially tyrosinase, are key players in the melanocyte
differentiation, as demonstrated by the dramatic consequences
of their mutations on melanin pigment production [11].
Some homozygous Mitf mutant mice can normally survive but
are microphthalmic, deaf, and completely white due to lacking
melanocytes [2,12], whereas some heterozygous Mitf mutant mice
show the striking phenotype of belly spotting [13]. In human,
MITF mutations are associated with 15% of Waardenburg syn-
drome type 2 (WS2). Waardenburg syndrome (WS) is an autoso-
mal dominantly inherited disorder of neural crest cells (NCC)
characterized by sensorineural deafness and abnormal pigmenta-
tion of the hair, skin and iris [14]. Clinically, WS is divided into
four types (WS1–4) based on the presence or absence of addi-
tional symptoms. WS2 is characterized as absence of additional
features.
We previously reported two mutations c.650G>T (p.R217I) and
c.575delC (p.T192fsX18) in the MITF gene in two different families
with WS2 [15]. To understand the functional consequences of
these mutations, we analyzed the subcellular distribution, expres-
sion and in vitro activities.lsevier B.V. All rights reserved.
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2.1. Reporter and expression constructs
The luciferase reporter containing the human TYR promoter
(pGL3-Tyr-Luc) and the expression constructs had been described
previously and were kindly provided by Vachtenheim et al. [16].
To generate MITF tagged with 3Flag at the N-terminus
(Flag-MITF), full length MITF cDNA (GenBank Accession No.:
NM_000248.2) was ampliﬁed from pCMV-MITF-HA and subcloned
into pCMV-3Flag (Sigma, St. Louis, WA, USA). The R217I MITF,
T192fsX18MITF and MITF lacking NLS (MITFDNLS) were generated
by using QuikChange II Site-Directed Mutagenesis (GE Healthcare,
Chalfont St. Giles, Buckinghamshire, UK). Further, a synthetic
oligonucleotide encoding the NLS (ERRRRF) of MITF was cloned
into pEGFP-N1 (Sigma) at EcoRI/BamHI site to add a NLS to the
N-terminus of GFP. All constructs were veriﬁed by direct nucleo-
tide sequencing.2.2. Cell culture, transfections, and luciferase reporter assays
The melanoma UACC903 cells or NIH3T3 cells were grown at
37 C under 5% CO2 in Dulbecco’s modiﬁed Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 100 U/ml of
penicillin/streptomycin as described [17]. Twenty-four hours be-
fore transfection, melanoma UACC903 cells were seeded at an
approximate 50% conﬂuency in 24-well plates. Cells were transfec-
ted with 5 ng of the reporter plasmid and 20 ng of the expression
plasmid, using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol, and 5 ng of
pCMV-b-gal (BD biosciences/Clontech, Palo Alto, CA, USA) was in-
cluded for normalization of transfection efﬁciency. The ﬁnal DNA
amount of each well was adjusted to 200 ng with empty vectors.
At 48 h after transfection, cells were washed with phosphate buf-
fered saline (PBS) and lysed with Reporter Lysis Buffer (Promega,
Madison, WI, USA). The extracts were assayed for luciferase and
b-galactosidase activity. Luciferase reporter assays were performed
using Luciferase Assay System (Promega) according to the manu-
facturer’s protocol. Luciferase activities were determined using
SIRIUS luminometer (Berthold Detection Systems GmbH, Pforz-
heim, Germany). As for competition assays, various amounts of
mutant MITF plasmids (20, 40, 80 ng) were mixed with a ﬁxed
amount of WT MITF (20 ng) and the reporter TYR plasmid (5 ng)
in the transfection. All reporter assays were conducted at least
three times and performed in triplicate on different days using dif-
ferent batches of cells. Data were analyzed using Prism 4 software
(GraphPad, Software Inc., San Diego, CA, USA).2.3. Western blot analysis
The melanoma UACC903 cells were transfected with 200 ng of
Flag-MITF or its mutant constructs using Lipofectamine 2000 re-
agent in 12-well plates. At 48 h after transfection, cells were lysed
in 2 SDS loading buffer, containing 1 mM phenylmethanesulfonyl
ﬂuoride (PMSF) (Sigma), and 0.2 mM b-mercaptoethanol supple-
mented with protease inhibitor cocktail (Sigma). Proteins were
separated on sodium dodecyl sulfate polyacrylamide gels (SDS–
PAGE) and transferred onto a polyvinylidene ﬂuoride (PVDF) mem-
brane (Millipore, Billerica, MA, USA). The membrane was blocked
in Tris-buffered saline supplemented with 5% non-fat milk for 1 h
at room temperature and then incubated overnight at 4 C with
mouse monoclonal anti-Flag M2 antibody (1:1000 dilution, Sigma).
After washing with Tris-buffered saline supplemented with 0.1%
Tween 20 (Sigma), the membrane was incubated for 1 h at room
temperature with a horseradish peroxidase-conjugated secondaryanti-mouse IgG antibody (1:10000 dilution, Sigma). Detection
were performed using the ECL plus Western blotting detection sys-
tem (GE Healthcare) according to manufacturer’s instruction.
2.4. Biotinylated DNA afﬁnity precipitation
The MITF-binding oligonucleotide derived from the promoter of
human TYR gene, 50-GAAAAGTCAGTCATGTGCTTTTCAG-30, and mu-
tated DNA-binding probe 50-GAAAAGTCAGTGTGCATCTTTTCAG-30
were biotinylated at the 50-terminus, and then annealed with its
complementary strand to generate WT and mutant double-
stranded oligonucleotides, respectively. The melanoma UACC903
cells were transfected with Flag-MITF, Flag-R217I, or Flag-
T192fsX18 using Lipofectamine 2000 reagent in six-well plates.
Forty-eight hours after transfection, cells were lysed by sonication
in HKMG buffer (10 mM HEPES, pH 7.9, 100 mM KCl, 5 mM MgCl2,
10% glycerol, 1 mM DTT, and 0.5% of Nonidet-P40) containing pro-
tease inhibitors. Cellular debris was removed by centrifugation.
Ten percent cell lysates were extracted and added 2 SDS/
0.2 mM b-mercaptoethanol for input immunoblotting. Remaining
cell lysates were brought to a ﬁnal volume of 1 ml and precleared
with 30 ll streptavidin-agarose beads (Sigma) with rotation at 4 C
for 1 h, then incubated with or without 8 lg of biotinylated
double-stranded oligonucleotide and 10 lg of poly(dI-dC).poly
(dI-dC) (Sigma) with rotation at 4 C for 20 h. Forty microliters
streptavidin-agarose beads were added and samples were incu-
bated for another 2 h at 4 C. Beads/DNA/protein or beads/protein
complexes were washed three times using cold ice HKMG buffer
and resuspended in 2 SDS/0.2 mM b-mercaptoethanol. Samples
were boiled at 95 C for 10 min and subsequently separated on
12% SDS–PAGE. Anti-Flag M2 antibody was used in the subsequent
immunoblotting.
2.5. Immunoﬂuorescence assays
The melanoma UACC903 cells or NIH3T3 cells were plated on
24-well plates and transfected with 50 ng of each MITF constructs.
At 48 h after transfection, cultures were ﬁxed in 4% paraformalde-
hyde for 30 min at room temperature. After permeabilized for 1 h
in PBS/0.2% Triton X-100 (Bio Basic Inc, Bailey Avenue Amherst,
NY, USA), they were incubated with blocking solution (PBS, 3% bo-
vine serum albumin, 5% goat serum) for 1 h. Incubation with pri-
mary anti-Flag M2 (1:600 dilution) was performed at 4 C
overnight. After washed with PBS/0.2% Triton X-100 three times,
ﬂuorescence-labeled secondary anti-mouse antibodies (1:300 dilu-
tion; Invitrogen) were incubated for 2 h in a dark room. After incu-
bation of 4,6-diamino-2-phenylindole (DAPI; Invitrogen) for 3 min,
cells were mounted in Fluoromount medium (Sigma) and ﬂuores-
cence images were examined with a laser scanning confocal sys-
tem installed on a Carl Zeiss microscope (Zeiss, Göttingen,
Germany) with a 63 oil immersion objective. Images were ana-
lyzed using the Metaphor software package.3. Results
3.1. Mutations of MITF in WS2
We previously identiﬁed two heterozygous mutations c.650G>T
(p.R217I) and c.575delC (p.T192fsX18) in the MITF genes in three
WS2 cases, presenting with deafness and heterochromia irides
[15]. The p.R217I is a missense mutation found in the basic domain
of bHLHZip region of exon 7, causing an arginine to isoleucine sub-
stitution at codon 217 (Fig. 1A). The p.T192fsX18 is a frameshift
mutation which generates different sequences starting at position
192 in exon 6 and introduces a premature stop codon at position
Fig. 1. Functional andWestern blot analysis of WS2-associated MITF proteins. (A) Schematic representation of theWT, R217I, and T192fsX18 MITF. The bHLH-Zip domain and
C-terminal transcriptional activation (TA) domain are shown. R217I is missense mutant and the arrow indicates mutation site in basic domain. T192fsX18 is a frameshﬁt
mutant and the ﬁlled box represents resulting frameshift from mutation site to premature stop codon. (B) Transcriptional activities of MITF and its mutants determined by
luciferase activity assays. The luciferase reporter plasmid Tyr-Luc were transiently transfected into melanoma UACC903 cells in combination with WT or mutant MITF
expression plasmids. (C and D) Effect of R217I or T192fsX18 mutants on WT MITF transactivity. Increasing amounts of mutant R217I or T192fsX18 expression plasmids were
cotransfected with a ﬁxed amount of WTMITF expression plasmid and the luciferase reporter plasmid Tyr-Luc. For (B)–(D), the basal level of luciferase was set as 1. Data from
all other transfections are presented as fold induction above this level. Luciferase activity was normalized by measuring b-galactosidase activity. Each value shown was the
mean ± SEM of three replicates from a single assay. The results shown were representative of at least three independent experiments. (E) Melanoma UACC903 cells were
transiently transfected with plasmids expressing either the WT or mutant variants of MITF. Proteins from whole cell lysates were analyzed by SDS–PAGE (12%) and the
expression of MITF was visualized using monoclonal antibody against Flag epitope (#P < 0.05, ##P < 0.01, as compared with the basal activity; ⁄⁄P < 0.01, as compared with the
WT; ns, not signiﬁcant; unpair Student’s t-test).
Fig. 2. DNA binding capacity of WS-associated MITF. The lysates of NIH3T3 cells
transfected with WT, R217I, and T192fsX18 MITF plasmids were incubated with or
without biotinylated double-stranded oligonucleotides of the MITF binding region
at the TYR promoter. And the DNA/protein complex was pulled down with
streptavidin-agarose beads. The precipitated proteins were separated on SDS–PAGE
and analyzed by immunoblotting using anti-Flag M2 antibody. DNA precipitation
demonstrates that R217I mutant retains the DNA-binding activity, whereas
T192fsX18 mutant lose capability to bind to DNA. As a negative control, WT MITF
protein did not bind to mutated double-stranded oligonucleotides.
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domain and transactivation domain.
3.2. Transcriptional activities of mutant MITFs
MITF can induce the transcription of target gene TYR and subse-
quently the expression of the melanocyte-speciﬁc enzyme tyrosi-
nase [7,18]. A luciferase reporter construct containing the TYR
promoter sequences was used to study if diseases-associated
mutations affected MITF activity. As shown in Fig. 1B, WT MITF
was able to increase the TYR promoter activity by about 55-fold,
consistent with previous reports [16–19]. However, the transactiv-
ity of R217I MITF was dramatically reduced as compared with WT,
whereas the T192fsX18 mutant failed to transactivate the TYR pro-
moter, indicating that R217I mutant was partially functional while
T192fsX18 mutant was loss-of-function.
Some loss-of-function mutant proteins may compete with their
WT protein binding to the promoter of target genes and inhibit the
activity of WT proteins, i.e. dominant negative effect. To determine
whether the R217I and T192fsX18 MITF were able to interfere with
WT MITF function, we carried out competition assays by cotrans-
fecting WT and R217I or T192fsX18 MITF expression plasmids to-
gether with the reporter plasmid. The TYR promoter activity
induced by WT MITF was increased with the addition of R217I,
consistent with its residual (50%) activity. T192fsX18 did not
show signiﬁcant effect on the transcriptional activity of WT MITF
(Fig. 1C and D).
3.3. Exogenous expression of MITF proteins
To investigate whether the disrupted function is caused by the
expression level of mutant MITF, we performed Western blot anal-
ysis on protein extracts from melanoma UACC903 cells transfected
with WT, R217I, or T192fsX18 MITF plasmid. As shown in Fig. 1E,
both WT and mutant MITF proteins were detected at the expected
size. There was no apparent difference between WT and mutant
MITF in the expression level.
3.4. DNA binding capacity of MITF mutants
To determine the DNA-binding capacity of WT and mutant MIT-
Fs, we used a biotinylated double-stranded oligonucleotide con-
taining MITF binding sequence to precipitate proteins from
UACC903 cells transfected with WT, T192fsX18, or R217I MITF
plasmids. As shown in Fig. 2, WT and R217I MITFs were able tobind speciﬁcally to the double-stranded DNA, consistent with their
transcriptional activity. T192fsX18 MITF lacks the bHLHZip DNA-
binding domain, thus was unable to bind the DNA. The WT MITF
protein was not able to bind a double-stranded oligonucleotide
with mutation in the E-box region, indicating the speciﬁcity of
DNA-binding (Fig. 2).
3.5. Subcellular distribution of WT and mutant MITF proteins
As a transcription factor, MITF is localized in the nucleus. Then,
we attempted to investigate if mutations altered the subcellular
distribution of MITF protein by using immunoﬂuorescence. As
shown in Fig. 3, WT and R217I MITF were only localized in the nu-
cleus, whereas T192fsX18 MITF was only localized in the cyto-
plasm. These results indicated that WT and R217I MITF produced
Fig. 3. Subcelluar localization of WS-associated MITF proteins and T192fsX18-NLS in melanoma UACC903 cells. WT MITF and its mutant proteins (a, d, g) were shown in red,
DAPI (b, e, h) revealing nucleus was shown in blue, and the merged images (c, f, i) were shown. Scale bar: 5 lm.
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nuclei, while T192fsX18 MITF was defective in the nuclear
translocation.
3.6. Functional analysis of nuclear localization signal of MITF
Protein localized in nucleus contains speciﬁc nuclear localiza-
tion signal (NLS) and can be recognized by transport protein to
cross nuclear pore complex (NPC) into nucleus to exert its function.
We speculate that the abnormal cytoplasmic distribution of
T192fsX18 MITF may due to its loss of NLS. Indeed, MITF contains
a putative NLS (NLIERRRRFNIN) between aa 210–221 at the C-
terminal basic domain [19] (http://cubic.bioc.columbia.edu/
predictNLS/). To examine whether this NLS is necessary for the
MITF function, we made a MITF lacking of aa 213–218 (i.e.
MITFDNLS). As shown in Fig. 4A, MITFDNLS failed to transactivate
the TYR promoter. Importantly, the MITFDNLS protein was localized
exclusively in the cytoplasm (Fig. 4B).
To examine whether this NLS sequences of MITF is sufﬁcient to
render cytoplamic protein into nuclei, we tagged the NLS sequence
of MITF (ERRRRF) to the N-terminus of green ﬂuorescence protein
(GFP). After transfected into the NIH3T3 cells, about 15% WT GFP
was distributed in the nucleus, 30% was localized in the cytoplasm,
whereas about 55% was seen in both cytoplasm and nucleus(Fig. 4B and C). However, NLS-tagged GFP signiﬁcantly increase
the nuclei localization to about 80%, and about 18% of NLS-tagged
GFP was observed in both cytoplasm and nuclei, while 2% of them
was seen in the cytoplasm only (Fig. 4B and C).
4. Discussion
MITF encodes a 419-amino-acid transcription factor containing
bHLHZip structure which is considered to bind DNA by the basic
domain, to dimerize via the HLH domain, and to be stabilized by
the Zip domain [1,2]. The carboxyl terminus of MITF contains a
transcriptional activation domain and plays an important role in
deﬁning the target genes [8]. Tyrosinase is a key enzyme for mel-
anin synthesis, which is encoded by the TYR gene, a melanocyte-
speciﬁc gene. MITF binds to the speciﬁc E-box motif (CATGTG)
within the promoter of TYR and initiates its transcription [7,8,18].
Few functional studies have been performed on human diseases-
associatedMITFmutations. Two non-sense mutations ofMITF caus-
ing WS2 were shown to abrogate DNA binding and transactivation
of the TYR promoter [17]. Another WS2-associated mutation,
c.892T>C (p.S298P), impaired MITF function due to loss of the
phosphorylation site by GSK3b [20]. We have shown here that
WS2-associated T192fsX18 and R217I mutations attenuated the
transactivity of MITF on TYR promoter.
Fig. 4. Functional analysis of NLS of MITF. (A) Transcriptional activities of WT MITF and MITFDNLS determined by luciferase activity assays. The luciferase reporter plasmid
Tyr-Luc were transiently transfected into melanoma UACC903 cells in combination with WT MITF or MITFDNLS expression plasmid. The basal level of luciferase was set as 1.
Data from all other transfections are presented as fold induction above this level. Luciferase activity was normalized by measuring b-galactosidase activity. Each value shown
was the mean ± SEM of three replicates from a single assay. The results shown were representative of at least three independent experiments (##P < 0.01, as compared with
the basal activity, unpair Student’s t-test). (B) Subcellular localization of MITFDNLS, EGFP, and EGFP-NLS in NIH3T3 cells was shown in green, DAPI revealing nucleus was
shown in blue, and the merged images were shown. Scale bar: 5 lm. (C) Frequency distribution of GFP and GFP-NLS in transfected NIH3T3 cells (⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, two-
way ANOVA followed by Bonferroni tests).
4130 H. Zhang et al. / FEBS Letters 586 (2012) 4126–4131The transactivity of R217I MITF was dramatically reduced as
compared with WT, whereas the T192fsX18 mutant failed to trans-
activate the TYR promoter. Further, neither R217I nor T192fsX18
MITF showed dominant negative effect on the WT MITF, thus hap-
loinsufﬁciency may be the underlying mechanism for WS2 patho-
genesis. Similar results were obtained when non-melanocytic cell
lines (human embryonic kidney 293 cells) were used (data not
shown). Although only homozygous mice with null mutations
showed apparent phenotype [21], MITF mutations were only iden-
tiﬁed in heterozygous forms in WS2 patients (http://gre-
nada.lumc.nl/LOVD2/WS/home.php?select_db=MITF). In our
cases, heterozygous T192fsX18 led to 50% reduction in the gene
dosage; however, it should be noted that heterozygous R217I re-
sulted in only 25% reduction in the gene dosage. The different
sensitivity of gene dosage between human and mice to MITF muta-
tion may be a possible explanation. Nevertheless, as we only gen-
otyped the known WS-related gene mutations in these patients,
we cannot exclude the possibility that other unappreciated gene
mutation, epigenetic effect or environmental factors may also con-
tribute to the syndrome.
Protein localized in the nucleus frequently contains speciﬁc NLS
that can be recognized by NLS-binding protein [22,23], and be
transported through the nuclear pore into the nucleus. The basic
domain of MITF may contain a NLS (210NLIERRRRFNIN221) [19]
(http://cubic.bioc.columbia.edu/predictNLS/). The T192fsX18 mu-
tant protein lacks NLS, which makes it not be recognized and trans-
ported into nucleus by NLS-binding protein, thus localized only in
cytoplasm. Interestingly, we found T192fsX18 MITF distributed in
both nucleus and cytoplasm in non-melanocytic NIH3T3 cell lines
(data not shown), which may be due to its small molecular mass
(predicted to be 23 kDa) to cross the nuclear pore complex via pas-
sive diffusion. The R217I mutation in the NLS did not impair the
nuclear localization potential of MITF, consistent with the previous
study [19,24]. They found that Mior–MITF encoded by the mouse
Mior allele, with a R216K substitution in the basic domain, showed
normal subcellular localization, suggesting that the nuclear trans-
location ability may not be affected by a substitution of one amino
acid residue in NLS.
The function of MITF NLS was further demonstrated by loss-of-
function and gain-of-function studies. In the loss-of-function
study, MITF with deletion of NLS localized exclusively in the
cytoplasma and failed to activate the TYR promoter. Conversely,addition of this NLS to the N-terminus of GFP enhanced the trans-
location of GFP into nucleus.
In summary, we have shown that two recent identiﬁed WS2-
associated mutations attenuated the transcriptional activity of
MITF. As both mutations were in the heterozygous form and lack
of dominant-negative effect, haploinsufﬁciency is the most reason-
able mechanism, where the normal MITF protein resulted from one
copy of the wild allele does not reach the threshold level necessary
for full function of the protein.Conﬂict of interest
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